After prostate surgery, test radiation plus hormone shots
Part of Cancer, Kidney & urinary clinical trials.
This trial studies whether giving a shorter-course radiation plan after prostate surgery, along with hormone shots (LHRH), can improve outcomes for people with higher-risk prostate cancer. You may be eligible if your PSA (a blood marker) is either still low but high-risk by pathology, or it has started to rise again after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and had a prostatectomy (surgery to remove the prostate).
- Your prostate cancer was high-risk based on the removed tissue or your PSA has started to rise after surgery.
- Your lymph nodes are negative (no spread to lymph nodes on imaging or pathology).
- Your cancer does not show bone spread on a bone scan (PET scans using certain tracers are allowed).
- Your PSA and testosterone need to be measured within about one month of starting the study, and PSA must meet study limits: under 0.4 if adjuvant, under 2.0 if salvage.
- You cannot have had prior hormone-blocking treatment (androgen deprivation), chemotherapy, or pelvic radiation, and you must have adequate blood counts and liver tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination of short-term hormone therapy (relugolix) and focused radiation (SBRT) can treat a certain type of prostate cancer that is considered favorable but has a higher genetic risk. It aims to find a less intense treatment that still works well.
This trial studies giving hormone treatment and radiation before prostate surgery to treat high-risk, locally advanced prostate cancer. It aims to improve cancer control by shrinking or controlling the tumor before removing it.
This study looks at combining radiotherapy and hormone therapy after prostate surgery to improve outcomes for men with prostate cancer. It uses samples and data from the larger RADICALS trial to understand which treatments work best.
This trial tests a new radiation approach for prostate cancer that has not spread. It combines different types of radiation with or without hormone therapy to see if this approach works better with fewer side effects.
This trial tests combining radiation therapy with two hormone-blocking drugs (darolutamide and degarelix) to treat intermediate-risk prostate cancer. The goal is to see if this combination is more effective and safe than radiation alone.
This trial tests whether giving hormone therapy (androgen deprivation therapy) before surgery can improve outcomes for men with high-risk prostate cancer. You will receive a special PSMA PET/CT scan to see how the cancer responds.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.